Join us for a webinar on May 7, 4:00 p.m. ET: 'Beyond Basics: Unraveling Challenging Type 2 Diabetes Cases.' Learn advanced treatment therapies and decision-making from experts. Register now: bit.ly/4bcyFTh

Support my JDRF One Walk www2.jdrf.org/site/TR?fr_id=…

Proudly presenting Part II of our #SpecialIssue on Preventing Metabolic Disease!
“Variability is the law of life, and as no two faces are the same, so no two bodies are alike.”—Sir William Osler, 1903. Covert Art: Julia Saxton
Noone and Mucinski et al. discuss individual response…

📰Pancreatic #diabetes may be nearly as common as type 1 diabetes, but much less is known about the condition.

Learn more about pancreatic diabetes in this Healio Exclusive from Endocrine Today: 👇

@RPratleyMD

healio.com/news/endocrino…

Real world data in millions of PPL with metabolic liver disease and #T2D reveals GLP-1RAs are associated with lower incidences of adverse CVEs and all-cause mortality #CVD #heartdisase Diabetologia link.springer.com/article/10.100…

#WCIRDC23
👏👏👏 to Yehuda Handelsman MD FACP, FNLA, FASPC, FAHA, MACE & the program committee for another superb World Congress on IR, DM & CVD 🌎! Full house every day!

🙏🏻 to all of the supporting companies!
Amgen 🧪🔬🧬 Bayer | Pharmaceuticals AstraZenecaUS Boehringer Ingelheim Eli Lilly and Company LexPharma Esperion Inc.

Healio TMIOA 🧬 Heart in Diabetes 🫀

Wrapping up Day of of Clinical Pathways in #T2D Care: Overcoming Inertia, Implementing Innovation

Dr. Tim Garvey, Richard Pratley MD, Amy Rothberg and Michele Tedder

In the dynamic ebb and flow of the GLP-1 space beyond #T2D #obesity does Eli Lilly and Company have the edge in portfolio depth, whereas Novo Nordisk leads in the breadth of expanding the evidence base for semaglutide? Discuss

Previous speculation that GI side effects of GLP1-RAs may lead to reduced food intake & associated weight loss

Our analysis shows weight reduction with tirzepatide (from SURPASS studies) is independent of reported side effects

dom-pubs.onlinelibrary.wiley.com/doi/epdf/10.11…

Big news: the FLOW trial of semaglutide for kidney protection in CKD stopped at pre-planned interim analysis. Trial now to close out and results will be available in first half of 2024. #FLOWtrial #semaglutide #ozempic

Exciting news for #DKD . Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis globenewswire.com/news-release/2…

Can’t tell if Penny is excited about the new mobile groomer or just happy she has had lots of treats #GoldenPenny

Harpreet Bajaj reviewing #diabetes #remission @ #diabetes dialog2023 hosted by the Barbara Davis Center for Diabetes - a new pathway for early #T2D

Congratulations to Professor Emeritus Patricia Brubaker University of Toronto Temerty Medicine U of T Physiology newly elected member of the Canadian Academy of Health Sciences CAHS/ACSS cahs-acss.ca/cahs-news/ #diabetes

Every decade of earlier diagnosis of T2 diabetes associated ~ 3–4 years of lower life expectancy

Data from 19 high-income countries, 1.5 million people

Need to delay onset of diabetes in young adults

sciencedirect.com/science/articl…

Now published

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist Phase 2 RCT

vs Dulaglutide 1.5mg & placebo

2% ⬇️ HbA1c
17% ⬇️ weight

sciencedirect.com/science/articl…

#SELECT trial demonstrates 20% reduction in MACE with #Wegovy . More ground breaking evidence of benefit for #GLP -1 Receptor Agonists. novonordisk.com/news-and-media…

Wegovy shown to reduce risk of heart attack, stroke in major cardiovascular trial - CNN apple.news/AKbRFOTRNRmOZj…

Early treatment of pts with #diabetes , #obesity and metabolic syndrome is beneficial but hard to accomplish for a variety of reasons. The final panel of Heart in Diabetes 🫀 discusses how to change the paradigm Yehuda Handelsman MD FACP, FNLA, FASPC, FAHA, MACE #HiD2023 Endocrine Today Erin D. Michos, M.D. Richard Pratley

Paul Ridker: Colchicine greatly lowers inflammatory risk for CVD but shouldn’t be given to pts with chronic #kidneydisease ; ziltivekimab may fill that gap if the ZEUS trial succeeds Heart in Diabetes 🫀 #HiD2023 Yehuda Handelsman MD FACP, FNLA, FASPC, FAHA, MACE Nephrology News & Issues #CardioTwitter